We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK immuno-oncology company Macomics has raised £4.24m in follow-on financing from its 2020 seed round as it aims to accelerate the development of its macrophage-based therapeutics portfolio.